The global neurothrombectomy devices market was valued at USD 672.7 million in 2023 and is projected to grow from USD 737.1 million in 2024 to USD 1,672.7 million by 2032, expanding at a compound annual growth rate (CAGR) of 10.8% during the forecast period (2024–2032). In 2023, North America led the market, accounting for a 41.92% share.

Neurothrombectomy devices are used to remove blood clots in patients suffering from ischemic stroke—a condition that occurs when a clot obstructs blood flow to the brain, cutting off oxygen and essential nutrients. According to the Centers for Disease Control and Prevention (CDC), ischemic strokes make up approximately 87% of all strokes reported in the U.S. The primary treatments include mechanical thrombectomy, in which specialists physically extract the clot using retrieval or suction devices, and thrombolytic therapy, which involves administering medication to dissolve the clot.

The market's growth is being driven by several factors, including the rising incidence of acute ischemic strokes, growing awareness of stroke treatments, and the increasing demand for minimally invasive procedures. The CDC reported in 2023 that over 795,000 people suffer strokes in the U.S. each year, with around 610,000 being first-time cases. Additional drivers include growing investments in R&D by key market players and the availability of favorable reimbursement policies that help cover treatment costs.

Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/neurothrombectomy-devices-market-106513

List Of Key Companies Profiled:

• Stryker (U.S.)

• Medtronic (Ireland)

• Penumbra, Inc. (U.S.)

• Boston Scientific Corporation (U.S.)

• Phenox GmbH (Germany)

• MicroVention Inc. (U.S.)

Neurothrombectomy Devices Market Trends:

Introduction of Advanced Devices to Drive Market Growth

The rising incidence of ischemic stroke has heightened the demand for more advanced neurothrombectomy devices. Despite the complexities involved in their design and manufacturing, leading market players are increasingly investing in research and development to introduce innovative solutions. The development of next-generation aspiration and suction devices, clot retrievers, and aspiration catheters equipped with advanced technology is a key factor fueling market expansion. These cutting-edge devices offer several advantages, including improved trackability, smoother clot retrieval, user-friendly operation, and enhanced procedural efficiency. For example, in February 2023, phenox Inc., a Wallaby Medical Company, received U.S. FDA 510(k) clearance for its pRESET Thrombectomy Device, designed for the treatment of acute ischemic stroke. The continuous efforts by manufacturers to launch technologically advanced products represent a major trend in the neurothrombectomy devices market and are expected to significantly boost product adoption throughout the forecast period.

Market Segmentation:

By Device Type Analysis

Reduced Procedural Time to Drive Growth of Aspiration Devices Segment (2024–2032)

The global neurothrombectomy devices market is segmented by device type into aspiration devices and clot retrievers. In 2023, the clot retrievers segment led the market, driven by their strong clinical outcomes and widespread use. These devices are preferred for their advanced technology, ease of use, and safety in removing clots from smaller cerebral vessels. However, the aspiration devices segment is projected to register the highest compound annual growth rate (CAGR) during the forecast period. This growth is primarily attributed to the shorter procedural time associated with aspiration techniques compared to clot retrievers. These devices are particularly effective in removing large clots that block major blood vessels, helping reduce the risk of distal embolization and improving patient outcomes.

By End-user Analysis

Advanced Infrastructure to Support Growth of Specialty Clinics

Based on end-user, the market is segmented into hospitals, specialty clinics, and others.

In 2023, the hospital segment held the largest share of the global market. Hospitals remain the primary setting for stroke treatment due to their comprehensive diagnostic capabilities, access to advanced imaging for rapid stroke assessment, and the urgent nature of treatment—ideally within 24 hours of symptom onset. Meanwhile, specialty clinics are expected to record a higher CAGR over the forecast period. The growth of this segment is fueled by the rise of dedicated stroke care units equipped with the latest medical technologies, specialized personnel, and integrated rehabilitation services. These clinics provide focused and efficient care, enhancing recovery outcomes and attracting more patients seeking specialized treatment options.

Neurothrombectomy Devices Market Growth Factors:

Rising Prevalence of Acute Ischemic Strokes to Propel Market Growth

A key factor driving the global neurothrombectomy devices market is the increasing prevalence of acute ischemic strokes. As incidence rates continue to rise, so does patient awareness and the demand for effective treatment options. Countries such as India, China, and Japan are actively promoting stroke management through cost-effective treatment options, government-led healthcare initiatives, and public awareness campaigns. These efforts, combined with a high burden of disease, are significantly contributing to market growth. According to the American Heart Association's 2023 report, the global age-standardized incidence rate of ischemic stroke is expected to reach 89.32 cases per 100,000 population by 2030. In addition to rising prevalence, the adoption of neurothrombectomy devices is further supported by ongoing technological advancements, a growing preference for minimally invasive procedures, and the availability of favorable reimbursement policies. Together, these factors are accelerating the market's expansion worldwide.

Restraining Factors:

High Cost of Neurothrombectomy Devices May Restrain Market Growth

Mechanical thrombectomy is a primary treatment for ischemic stroke, involving the physical removal of blood clots by a specialist using advanced medical devices. As a highly specialized procedure, it requires precision-engineered equipment that is both complex to design and costly to produce. Moreover, the procedure must be performed within a critical window of 6 to 24 hours from the onset of stroke symptoms, adding urgency and logistical challenges. According to a report by the National Institute for Health and Care Excellence (2019), the cost of stent retrievers ranges from USD 625 to USD 1,530 per unit, while aspiration catheters can cost between USD 1,700 and USD 5,700 per unit. In addition to the high cost, limited awareness and the lack of specialized thrombectomy centers in many emerging markets further hinder the widespread adoption of these devices. These barriers, particularly in low- and middle-income countries, pose significant challenges to market expansion.

Regional Analysis:

North America dominated the neurothrombectomy devices market in 2023, with a market size of USD 282.0 million. This dominance is attributed to the rising prevalence of ischemic stroke and the strong presence of leading medical device manufacturers in the region. Additionally, favorable reimbursement policies in the U.S. and Canada, along with a growing number of patients requiring acute ischemic stroke treatment, are expected to drive continued market growth.

Europe is projected to record a significant CAGR during the forecast period, supported by the increasing adoption of cost-effective treatment options and a growing number of mechanical thrombectomy procedures. Countries such as Germany, the U.K., and France are at the forefront of this trend. For example, the National Institute for Health and Care Excellence (NICE) reported that a single 24-hour specialty clinic in England can perform 5 to 6 mechanical thrombectomy procedures each week.

Asia Pacific is expected to witness the highest CAGR, driven by a rapidly aging population and increasing awareness about stroke treatment. The rising establishment of stroke units in hospitals across major countries—including China, Japan, and India—is further fueling market expansion. According to a 2020 report by the Medical Journal of Dr. D.Y. Patil Vidyapeeth, India had approximately 35 dedicated stroke units, primarily in private healthcare facilities.

In contrast, Latin America and the Middle East & Africa are expected to hold a smaller market share throughout the forecast period. Growth in these regions is limited by high treatment costs, insufficient reimbursement frameworks, and a lack of trained specialists and advanced healthcare infrastructure.

Key Industry Developments:

• November 2023 – BrainCool AB partnered with Wallaby Medical to conduct a local clinical trial across three leading Chinese university hospitals. The trial aims to combine Targeted Temperature Management (TTM) with thrombectomy, supporting market registration efforts in China for BrainCool’s two TTM devices: the NeuroChill System and the BrainCool System.

• March 2022 – Medtronic plc launched India’s first dedicated registry to collect real-world data on the use of revascularization devices in treating acute ischemic stroke (AIS) patients, marking a significant step in stroke care advancement.